Separate the change into material, geometry, and process before you decide

Lot 22-1147 arrived on a Tuesday. Same catalog number, same certificate of analysis format, same dimensional drawing. By Thursday the internal standard area counts on our EPA 8260 volatiles run had dropped 11.4% against the trend line, and the check standard failed on three analytes. The vial was the only input that had changed. That is the moment where a written revalidation trigger earns its keep, because without one you are arguing about it in real time with a review deadline on the bench.

The question this article answers is narrow: when a vial supplier, molding lot, or component specification changes, which changes force revalidation, which only need verification, and how do you write the change-control entry so an inspector reads it and moves on. I have written and defended enough of these entries to know that the technical work is usually easier than the paperwork. The paperwork is where the finding comes from.

Separate the change into material, geometry, and process before you decide anything

Most teams treat a vial change as one event. It is not. I break every incoming change notice into three axes, because the revalidation triggers on each axis are different.

Material. Glass hydrolytic class, resin grade, septum elastomer formulation, liner film, and any colorant or lubricant. A move from Type I borosilicate to Type I borosilicate from a different furnace is a material change even though the spec sheet line reads identically. So is a septum supplier switching from a 55 Shore A silicone to a 50 Shore A silicone with the same part number.

Geometry. Crimp finish dimensions against the GPI 13 mm and 20 mm profiles, neck ID, seat depth, septum thickness, and the critical one most people skip: the sealing bead radius where the septum meets the neck land.

Process. Forming station parameters, annealing profile, septum molding cure time, and the assembly step (whether the septum was seated by hand, by a semi-automatic capper, or by a fully automated line). A supplier moving the capping step to a different line is a process change even if the parts are identical.

Write those three lines down before you open the change-control form. If you cannot fill them in, you do not yet know what changed, and no amount of validation will fix that.

Changes that force revalidation, and changes that only need verification

The distinction I use is simple. Revalidation means you re-run the affected method performance characteristics (system suitability, calibration, check standard, and any analyte-specific recovery or carryover checks). Verification means you run a documented side-by-side comparison and file the data without touching the validated method text.

The deciding factor is whether the change can plausibly move a measured result. Material and geometry changes can. Paperwork and packaging changes cannot.

Force revalidation

• Glass hydrolytic class change (Type I to Type II, or Type I to a lower-boron formulation). This moves extractables and can shift pH-sensitive analytes.
• Septum elastomer formulation change, including a cure-system change (peroxide to platinum-cured silicone). This is the single most common source of ghost peaks I have chased. If your method has low-level analytes in the ppb range, treat this as a full revalidation.
• Liner film change (PTFE to a different PTFE grade, or adding a silicone film). Silicone films can bleed siloxanes into headspace methods.
• Sealing geometry change at the bead or seat. This affects leak rate and, in headspace work, pressure retention.
• New manufacturing site for the same part number, even with identical drawings.
• Any change that touches the neck finish dimensions outside the GPI tolerance band.

Verification only

• Certificate of analysis format change with identical measured values.
• Packaging change (case count, bag material, tray layout) that does not touch the primary container.
• Label or print change on the vial body.
• Supplier name change where the manufacturing site, resin, and process are unchanged and documented.
• Lot-to-lot variation within an established specification, where you already have a control chart and the new lot sits inside the historical limits.

For the verification cases, run a side-by-side of at least three vials from the new lot against three from a retained reference lot, using the same instrument, same column, same sequence position. Document the comparison in the change-control record. That is enough for an inspector on a packaging change. It is not enough for a septum change.

Lot-to-lot drift is not a supplier change, and inspectors know the difference

Here is where a lot of teams get caught. A new lot arrives from the same supplier with the same part number and the same certificate. Nobody files a change-control entry because nothing “changed.” Then the check standard drifts and you have no documented trigger.

The fix is to treat lot-to-lot variation outside your control chart limits as an automatic revalidation trigger, written into the method or the supplier agreement. Set the limit from your own data. If your internal standard area counts have a historical RSD of 3.1%, a new lot that shifts the mean by more than 5% is a trigger. That number comes from your chart, not from a generic rule.

This is the same logic that governs a supplier qualification program. If you have not built the control chart yet, that is the prerequisite, not the revalidation. For context on how a vial behaves as a regulated component rather than an accessory, see our note on why the vial is part of the regulated method.

Write the change-control entry so an inspector can follow the logic in one pass

I have reviewed hundreds of these entries. The ones that pass share a structure. The ones that get cited almost always fail on the same two points: the risk assessment is missing, or the verification data does not actually test the thing that changed.

The six fields that carry the entry

• What changed, in one sentence, with the specific attribute. Not “supplier change.” Write “septum elastomer cure system changed from peroxide to platinum-cured on the 20 mm headspace closure, effective lot 23-0401.”
• Why it changed. Supplier consolidation, capacity move, formulation update. One line.
• Risk assessment against the method. Name the analytes and the mechanism. If the septum cure changed, name the siloxane and the target ions you expect to see shift.
• Classification: revalidation or verification, with the justification. Cite the decision rule above.
• The data. Attach the side-by-side, the system suitability, and the check standard results. Reference the sequence file and the instrument ID.
• The disposition and the effective date. Which lots are released under the old method, which under the new, and the cutover date.

What “risk assessment” actually means here

It means you name the failure mode and the measurement that would detect it. For a septum change in a headspace method, the failure mode is siloxane bleed raising baseline and creating ghost peaks at specific m/z values. The detection measurement is a blank run and a low-level standard, run in sequence position 1 and position 6. If your entry says “risk assessed as low” with no mechanism named, an inspector will ask you to justify it, and you will not have the data.

For a glass change, the failure mode is extractables shifting the baseline or adsorbing a low-level analyte. The detection measurement is a solvent blank stored in the vial for 24 hours at 40 °C and injected against a freshly prepared standard.

Field case one: the septum cure change that moved the internal standard 11%

The symptom was the one I opened with. Lot 22-1147, same part number, same certificate. The internal standard area counts dropped 11.4% against the trend line over five runs, and the check standard failed on three analytes at the low calibration point.

The measurement that identified it was a blank injection in sequence position 1. The blank showed a cluster of siloxane ions (m/z 73, 147, 207, 281) at roughly 2.5 times the historical blank level. That pointed straight at the septum. The supplier confirmed a cure-system change on the closure, made at the molding line, communicated as a “process improvement” with no change notice.

The fix was a full revalidation of the affected method, a supplier change-notice requirement written into the purchase agreement, and a blank-in-position-1 check added to the system suitability criteria. The revalidation itself took four days. The supplier negotiation took six weeks. The lesson: the change-control entry should have existed before the lot shipped, and the only way to guarantee that is a contractual notice requirement.

Field case two: the neck finish that passed the drawing and failed the capper

A different supplier, a different failure. The vials passed incoming dimensional inspection against the drawing. The crimp capper on the filling line started throwing seal failures at 1.8% against a historical rate of 0.2%. The leak test (dye immersion, 30 seconds) caught them, but only after the capping step.

The measurement that identified it was a sectioned vial under a profile projector. The sealing bead radius was 0.05 mm larger than the reference lot. Within the drawing tolerance, but outside the window the capper’s crimp jaw was set for. The crimp force was 1.4 kN against the reference 1.2 kN, and the extra radius meant the jaw did not fully seat the septum.

The fix was a re-set of the capper and a revalidation of the headspace method with the new lot, because a partially seated septum changes the headspace pressure and the equilibrium. The change-control entry had to document the geometry change, the capper adjustment, and the revalidation. The inspector’s question was not “why did you change the capper,” it was “how did you know the geometry changed before the seal failed.” The answer was the profile projector check, added to the incoming inspection after this case.

If you run headspace work, the closure geometry matters more than the vial body. Our headspace vial notes cover the pressure-retention side of this in more detail. If you run GC with a split/splitless inlet, the GC vial geometry and septum seat are the equivalent variables.

The decision checklist, with the numbers that matter

This is the table I keep on the wall. It maps the change type to the action and the acceptance criterion. The numbers are the ones that have held up in my own methods; yours will come from your control charts.

The ±10% check standard window and the 2.0% system suitability RSD are common defaults. If your method has tighter limits, use them. The point is that the criterion is written down before the change, not negotiated after the run fails.

What to put in the supplier agreement so the notice arrives before the lot

None of this works if the supplier changes the part and tells you afterward. The change-control entry is only as good as the notice that triggers it. I put four clauses in every vial purchase agreement, and I have never regretted any of them.

• Written notice of any change to material, geometry, or manufacturing site, at least 90 days before shipment. No exceptions for “minor” changes. The supplier does not get to decide what is minor.
• Lot traceability to the molding line and the resin lot. If a failure traces back to a lot, you need to know which line and which resin batch.
• Retained samples held for the shelf life of the product, so you can run a side-by-side against the original lot when a question comes up two years later.
• Right to audit the manufacturing site, with the audit scope covering the forming station and the septum molding line.

The 90-day notice is the one that matters most. It gives you time to schedule the revalidation, order the reference lot, and write the change-control entry before the new lot is on the bench. Without it, you are doing the revalidation under a review deadline, which is when mistakes happen.

Where the revalidation data actually goes, and what it does not need to cover

The revalidation data goes into the method performance section of the change-control record, not into the method text. The validated method text does not change unless the acceptance criteria change. This is the distinction that trips up teams who think a vial change means rewriting the method.

What the data does not need to cover: routine audit documentation and the regulatory method text itself. Those are separate documents with their own owners. Keep the change-control entry focused on the change, the risk, the data, and the disposition. If you find yourself writing about the method’s regulatory basis, you have drifted into a different document.

For the regulatory frame, the method text you are validating against is set by the governing method (EPA 8260, EPA 8270, USP <621> for chromatography, and so on). The EPA SW-846 test methods are the reference for the waste and materials work; the container performance requirements sit in the method, not in the supplier’s catalog. For chromatographic method detail, the Restek technical resources and the Agilent GC columns and accessories pages are where I send new analysts to understand what the column and inlet expect from the sample container. The Thermo Fisher chromatography and sample handling library covers the autosampler side, which is where geometry failures show up first.

The decision rule I would write into the SOP tomorrow

If the change touches material, geometry, or manufacturing site, revalidate. If it touches only paperwork or packaging, verify with a documented 3-versus-3 side-by-side. If a new lot moves a monitored measurement beyond your control chart limits, revalidate regardless of what the supplier says changed. Write the trigger, the acceptance criterion, and the 90-day notice clause into the SOP and the purchase agreement, and the next lot 22-1147 becomes a scheduled task instead of a Thursday afternoon argument. The vial is a small part of the method, but it is the part that arrives in a box with a certificate that may or may not describe what is actually inside. Treat the certificate as a claim to be verified, not a fact to be filed.

References & further reading

Related resources from our lab consumables network:

• Vial at vials-filters.com
• Headspace Vial at headspacevialsupplier.com
• Gc Vial at gcvialfactory.com
• Reagent Bottle at reagentbottleforsale.com

External references and standards:

• Agilent chromatography consumables and columns
• Thermo Fisher chromatography and sample handling
• U.S. EPA SW-846 test methods for waste and materials
• Restek technical resources for chromatography